(Q48478885)

11 February 2018

title

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. (English)

1 reference

11 February 2018

0 references

A B Kimball

1

1 reference

11 February 2018

K B Gordon

2

1 reference

11 February 2018

S Fakharzadeh

3

1 reference

11 February 2018

N Yeilding

4

1 reference

11 February 2018

P O Szapary

5

1 reference

11 February 2018

B Schenkel

6

1 reference

11 February 2018

C Guzzo

7

1 reference

11 February 2018

S Li

8

1 reference

11 February 2018

K A Papp

9

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 April 2012

1 reference

11 February 2018

British Journal of Dermatology

published in

1 reference

11 February 2018

volume

166

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

page(s)

861-872

1 reference

11 February 2018

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Cutaneous squamous-cell carcinoma in patients treated with PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Risk of Cutaneous Carcinoma in Patients Treated with Oral Methoxsalen Photochemotherapy for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Biologic therapies in psoriasis: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Relapse, rebound, and psoriasis adverse events: an advisory group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10901.X

10.1111/J.1365-2133.2012.10901.X

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

release_ucpajfwhkfgijgqlytjnqwapqa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ucpajfwhkfgijgqlytjnqwapqa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

11 February 2018